SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice



Ali, Amar, Bain, Steve, Hicks, Debbie, Jones, Phillip Newland, Patel, Dipesh C, Evans, Marc, Fernando, Kevin, James, June, Milne, Nicola, Viljoen, Adie
et al (show 2 more authors) (2019) SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. DIABETES THERAPY, 10 (5). 1595 - 1622.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Uncontrolled Keywords: Anti-diabetic medicines, Cardiovascular disease (CVD), Clinical guidance, Heart failure (HF), Oral glucose-lowering medicines, Practical treatment selection, SGLT2 inhibitors (SGLT2i), Therapy choice, Type 2 diabetes mellitus (T2DM)
Depositing User: Symplectic Admin
Date Deposited: 07 Aug 2019 11:25
Last Modified: 06 Oct 2021 18:10
DOI: 10.1007/s13300-019-0657-8
Open Access URL: https://doi.org/10.1007/s13300-019-0657-8
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3051194